PCD4: THE IMPACT OF SECONDARY EVENTS ON THE COST OF ACUTE MYOCARDIAL INFARCTION  by O'Brien, J et al.
68 Abstracts
Risk assessment and intervention programs that target
treated but uncontrolled hypertensives can be expected to
yield substantial economic benefits in addition to pre-
venting cardiovascular morbidity and mortality.
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OBJECTIVES: To compare the long-term clinical and
economic outcomes of elderly (75 years) versus younger
acute coronary syndrome patients. METHODS: We used
the Duke Cardiovascular Databank to identify patients
with a recent (6 weeks) myocardial infarction or unsta-
ble angina, index cardiac cath between 1986 and 1997,
significant coronary artery disease (CAD), and no previ-
ous cardiac procedures. Follow-up extended through
1998. We modeled clinical events (death, MI, coronary
artery bypass graft surgery (CABG), percutaneous coro-
nary intervention (PCI), and other rehospitalizations) to
12 years for pts with censored follow-up. We modeled in-
patient and outpatient medical costs for all patients using
inpatient costs from the GUSTO IIb clinical trial and
other secondary data sources. RESULTS: Elderly (n 
1401) vs. younger (n  8475) patients were more likely
female (58% vs. 32%) and non-smokers (41% vs. 69%),
had greater history of congestive heart failure (25% vs.
14%) and cerebral vascular disease (17% vs. 9%), less
single vessel disease (30% vs. 46%) and more three vessel
disease (43% vs. 26%), and greater 30-day mortality
(9.8% vs. 3.2%). While median 12-year medical costs
were greater for younger ($57,475) than for elderly
($53,431) patients, mean survival was less for elderly pa-
tients (6.4 vs. 9.3 years) yielding greater costs per year of
survival ($8075 vs. $6037) for the elderly. CONCLU-
SIONS: CAD patients undergoing an initial cardiac cath
after age 75 represent a high-risk group undetected by
current CAD screening algorithms. These findings point
to the need for improved screening tools and disease
management strategies in high-risk, pre-CAD popula-
tions.
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OBJECTIVES: Stroke is the third leading cause of death
and a leading cause of disability. We determined inci-
dence, and total direct costs of stroke by stroke type, age
group, gender and race. METHODS: We used an inci-
dence approach and aggregate national data sources to
determine 1998 US direct medical cost of stroke from a
societal perspective. We modeled the disease from first
hospitalization to end of first year. A sensitivity analysis
varied prevalence and utilization of each cost factor
around a base case. RESULTS: The incidence of first
stroke is 232/100,000 population of which 82% are is-
chemic strokes. The total annual costs of a first time
stroke are $25.2 billion. The first hospitalization ac-
counts for 20% of costs but all hospitalizations together
in the first year account for the highest proportion of
costs (65%, $15.9 billion). Those with subarachnoid
hemorrhagic stroke ($18,461) had first hospitalization
costs per stay more than three times higher than ischemic
stroke ($5,417) and more than two times higher than in-
tracerebral hemorrhagic stroke ($7,709). Also high are
costs for chronic disability care, which are $5.5 billion,
primarily home care ($3.9 billion). Sensitivity analysis
showed a maximum variation in cost from $15.8 to
$35.8 billion when varying incidence estimates. CON-
CLUSION: The societal cost burden is quite high and
caused primarily by disability factors. Although ischemic
stroke accounts for the highest total costs due to its
higher incidence, subarachnoid hemorrhagic stroke ac-
counts for more deaths and much higher first hospitaliza-
tion costs. This study demonstrates a high combined
acute and chronic care burden for stroke patients.
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OBJECTIVES: The importance of subsequent events on
health care costs following acute myocardial infarction
(AMI). METHODS: Patients with AMI (first admission 
index) were identified from Massachusetts (MA) 1996/
1997 patient-level discharge databases. Secondary events
(i.e., AMI, angina, CABG, PTCA, coronary angiography,
ischemic stroke, TIA, other related cardiovascular condi-
tions) occurring within 12 months were assessed in terms
of hospital costs, length of stay, discharge disposition
and post-acute care costs. These data were supplemented
by five additional state databases, fee schedules, other
agency and survey data, and the literature. All costs are
reported in 1998 US dollars adjusted for medical infla-
tion and cost-to-charge ratios. Log transformation was
used to address highly skewed distributions. RESULTS:
Of the 8,037 MA AMI patients, 86% were discharged
alive, and 54% of them were readmitted for another
event, 49% more than once. Of those readmitted, 8.9%
were hospitalized for a second AMI, 1.4% for a stroke. A
second AMI increases the use of post-discharge formal
health care services (e.g., skilled nursing facility, rehabili-
tation, home health care) by 19% and a stroke by 52%.
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Managing a patient with a second AMI was 30% more
costly ($34,700 versus $26,600 for single AMI). A stroke
results in a 140% increase ($63,836). Occurrence of any
secondary event increases the first year management
costs by approximately 36% (range: 4% for angina to
149% for CABG). CONCLUSIONS: To properly esti-
mate the cost of AMI, the impact of secondary events
needs to be considered. The increased economic burden
resulting from these secondary events goes beyond the
additional cost of another hospitalization. This informa-
tion should be incorporated into economic models that
address drug therapies for secondary prevention in AMI.
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OBJECTIVES: Recent advances in left ventricular assist
device (LVAD) technology have made this therapy a life-
saving bridge to orthotopic heart transplant (OHT) in
patients with heart failure who fail maximal medical ther-
apy, including positive inotropic support. This study ex-
amined the costs of LVAD versus traditional intravenous
positive inotropic support strategies in patients awaiting
OHT. METHODS: To determine the economic impact
of using either LVAD or positive inotropic support strat-
egies for patients awaiting OHT, we retrospectively ex-
amined the itemized inpatient billing records of all pa-
tients who underwent OHT in 1993 (N  18) and 1996
(N  32) at our center. PreOHT costs (in 1997 US $) were
calculated for each billed item using institutional cost:charge
ratios. Items were categorized as pharmacy, procedure,
laboratory, bed, blood product, respiratory care, and sup-
ply. Professional fees were excluded from the analysis. Per
diem costs were calculated to control for interpatient dif-
ferences in length of stay. RESULTS: LVAD support was
utilized in 10 patients, and the remaining 40 patients re-
ceived only positive inotropic therapy prior to OHT. The
groups were demographically and clinically similar. Pre-
OHT length of stay was 113  63 days vs 71  46 days
(LVAD vs positive inotrope groups; P  0.02). Total pre-
OHT per diem costs were $3651  1510 for LVAD pa-
tients and $2625  602 for positive inotrope patients (P 
0.01). Although per diem pharmacy and bed costs were
similar, costs in the LVAD patients for procedures ($794 
667 vs $237  289), laboratories ($436  280 vs $260 
138), blood products ($122  148 vs $12  16), respira-
tory care ($222  263 vs $61  123), and supplies ($223 
131 vs $141  62) were significantly higher than in posi-
tive inotrope-supported patients (P  0.01 for all). CON-
CLUSIONS: In this study, length of stay and per diem
costs were higher in patients requiring LVAD implanta-
tion as a bridge to transplant. These increased costs may
be justified given the extremely high mortality of these
patients in the absence of LVAD support.
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The ministry of health is preparing a national rational
drug consumption program in Turkey. It is a must to ra-
tionalize drug use and effectively reorganize reimburse-
ment of drugs in order to minimize costs and maximize
effective treatment. However, due to the lack of studies
on drug prescription habits, rational drug prescribing
and cost analysis, it is not possible to make effective
changes. OBJECTIVE: We have conducted a pilot study
on reimbursed prescriptions of Emekli Sandigi and Bag-
Kur from January 1998-between September 1999 and
evaluated antihypertensive drugs. METHODS: 2278 pre-
scriptions from Ankara Numune Hospital and the social
security systems (Emekli Sandigi, Bag-Kur) were chosen
randomly. Medical information included the length of
time medications were extracted. RESULTS: Cost analy-
sis of antihypertensives showed that the average total
cost of antihypertensive treatment was $9.09 (range
$0.89–$30.52) per patient and the most prescribed anti-
hypertensive drug class was ACE inhibitors (25%).
CONCLUSIONS: Taking the results of this pilot study
into consideration, a master study for Turkey is planned
which will also include postgraduate training programs
to enhance rational prescription. In October 1999 the
first program was held in Patalya Hotel-Ankara by the
ministry of health.
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The use of such anti-platelet agents as aspirin and ticlopi-
dine have not been approved in Japan for use in the pre-
vention of the recurrence of cerebrovascular diseases that
include cerebral infarction. Cilostazol is an anti-platelet
agent indicated for the treatment of ischemic symptoms,
including ulcer, pain, and cold sensation in chronic arterial
occlusion, but it also has been confirmed to be effective
over placebo with respect to the prevention of cerebral inf-
arction recurrences through a randomized, double-blind,
placebo controlled, multi-center clinical trial (RCT). OB-
